Genetic and Environmental Risk Factors for Hemorrhagic Stroke-GERFHS III (GERFHS-III)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00930280|
Recruitment Status : Active, not recruiting
First Posted : June 30, 2009
Last Update Posted : February 7, 2018
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||1260 participants|
|Official Title:||Genetic and Environmental Risk Factors for Hemorrhagic Stroke|
|Study Start Date :||July 2008|
|Estimated Primary Completion Date :||June 2021|
|Estimated Study Completion Date :||June 2021|
Hemorrhagic stroke cases
People who have had a hemorrhagic stroke, specifically an intracerebral hemorrhage, and live within a 100 mile radius of the University of Cincinnati.
Healthy Control Subjects
Healthy volunteers who are randomly identified in the same 100 mile radius of the University of Cincinnati and have not had a hemorrhagic stroke.
- The analysis of the presence of specific genetic markers associated with hemorrhagic stroke versus the control group. [ Time Frame: Ongoing to be completed at the end of June 2013. ]Identification of specific genetic markers for each subject will be measured by gene assay using the Affymetrix chip. We are looking for SNPs that persist after controlling for traditional risk factors such as hypertension, smoking exposure, diabetes, alcohol use, anticoagulant use, hypercholesterolemia and APOE alleles.
- Analysis of risk factors such as age, race, gender, current smoking, heavy alcohol use, use of anticoagulants, diabetes, hemorrhagic stroke family history, hypertension, etc. in people with hemorrhagic stroke versus the control group. [ Time Frame: Ongoing to be completed at the end of June 2013. ]Traditional risk factors will be identified through self report during interview and by hospital chart notes for the case subjects. Identification of the APOE alleles for each subject will be done on their genetic sample.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00930280
|United States, Ohio|
|University of Cincinnati Department of Neurology|
|Cincinnati, Ohio, United States, 45267-0525|
|Principal Investigator:||Daniel Woo, M.D.||University of Cincinnati Department of Neurology|